ANVS vs. SBTX, NKTX, NBTX, URGN, QTTB, AVIR, VTYX, KMDA, ADCT, and VNDA
Should you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include Silverback Therapeutics (SBTX), Nkarta (NKTX), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), ADC Therapeutics (ADCT), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Silverback Therapeutics (NASDAQ:SBTX) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership.
Annovis Bio has a consensus price target of $23.50, suggesting a potential upside of 258.78%. Given Silverback Therapeutics' higher probable upside, analysts plainly believe Annovis Bio is more favorable than Silverback Therapeutics.
Annovis Bio received 1 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 95.00% of users gave Annovis Bio an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.
In the previous week, Silverback Therapeutics and Silverback Therapeutics both had 1 articles in the media. Silverback Therapeutics' average media sentiment score of 1.00 beat Annovis Bio's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the news media.
Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.
Silverback Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.
Annovis Bio's return on equity of -29.62% beat Silverback Therapeutics' return on equity.
74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by company insiders. Comparatively, 38.3% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Annovis Bio beats Silverback Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Annovis Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Annovis Bio Competitors List
Related Companies and Tools